FDA supplemental approval: Butalbital, Acetaminophen, Caffeine AND Codeine Phosphate (REMS)

AI Summary

The FDA approved a supplemental application for a Risk Evaluation and Mitigation Strategy (REMS) for a fixed-dose combination capsule containing butalbital, acetaminophen, caffeine, and codeine phosphate (Hikma). This is a regulatory compliance action and does not report clinical trial results, efficacy, or safety outcomes.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for an existing combination analgesic; this is a regulatory action, not a clinical efficacy study.

Study design

As stated by the source record.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This approval action establishes that the sponsor has implemented a REMS program as required by the FDA for this opioid-containing combination product. Healthcare professionals and patients should be aware of any restrictions, monitoring requirements, or patient education materials mandated by the REMS program; however, this record does not specify the REMS requirements themselves.

Caveats

• This record does not contain clinical trial data, efficacy outcomes, safety results, or comparative effectiveness.
• The specific REMS requirements (e.g., restricted distribution, prescriber/patient education, monitoring) are not detailed in this regulatory record.
• Clinical indication, population, dosing schedule, and contraindications are not specified in this approval notice.
• No adverse event data, trial results, or postmarket surveillance findings are reported in this regulatory record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.